ImmunoClin Corp (Grey Market:IMCL:US)

Delayed Data
As of Jun 20
 0.00 / 0.00%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Immunoclin Corp. is a healthcare company. The company is focused on developing preventive medicines to fight inflammatory conditions that are the cause of pathologies in conditions affecting the majority of the human population such as infections, cancer, cardiovascular disease and dementia, including Alzheimer's disease. Its products include Multi-Variant Atherosclerosis Risk Assessment, an algorithm to analyze the multi variant data to identify people who are at risk of having heart attack; Genetic Alzheimer's Risk Discovery, a genetic test for multiple genetic variants associated with risk of the common form of dementia, Alzheimer disease; PRIMALEUKIN, commonly known as interleukin-22, has a position as a combined antibacterial, anti-fungal and antiviral agent, harnessing and amplifying the body's own natural defense against, and recovery from infection;and DACTELLIGENCE Technology, a technology to engineer a sensor using a mathematically modeled fractal dactyl surface creating confined cages. Immunoclin was founded on February 8, 2011 and is headquartered in Washington, DC.

Contact Information

Immunoclin Corp.
1420 North Street
Washington District Of Columbia 20005
P:(202) 838-8141
Investor Relations:



Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Dorothy H. BrayPresident, Chief Executive Officer & Director
Chad S. JohnsonCOO, Secretary, Director & General Counsel
James Scott MunroCFO, Treasurer & Principal Accounting Officer
Khadija BenlhassanDirector & Chief Scientific Officer